Objective: To investigate relationships between tau-PET binding and other established Alzheimer's disease (AD) markers in cognitively normal individuals at increased risk of AD. Methods: One-hundred-nineteen late-middle-aged and older adults with a parental or multiple-sibling history of AD (PREVENT-AD cohort, mean age=67±5) underwent tau PET ([18F]flortaucipir), β-amyloid (Aβ) PET ([18F]NAV4694), and cognitive assessment. A subsample of 74 participants also had CSF phosphorylated (p)-tau data available. We investigated regional tau SUVR differences between Aβ-positive and Aβ-negative individuals using general linear models adjusted for age and sex. In regions showing higher flortaucipir binding in Aβ-positive individuals, we assessed wheth...
Aims: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especial...
BACKGROUND: Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimers di...
Abstract PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzhe...
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF)...
Hyperphosphorylated tau protein in the form of neurofibrillary tangles is one of the major pathologi...
OBJECTIVE: To investigate the association between discordant β-amyloid (Aβ) PET and CSF biomarkers a...
Background: Different tau biomarkers become abnormal at different stages of Alzheimer’s disease (AD)...
Objective: To investigate the association between discordant amyloid-β PET and CSF biomarkers at bas...
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's di...
Objective To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cort...
BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progre...
OBJECTIVE: To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cor...
Background Combining PET amyloid-β and tau imaging may be critical for tracking disease progression ...
Background: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease prog...
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on function...
Aims: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especial...
BACKGROUND: Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimers di...
Abstract PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzhe...
Purpose: In vivo Alzheimer’s disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF)...
Hyperphosphorylated tau protein in the form of neurofibrillary tangles is one of the major pathologi...
OBJECTIVE: To investigate the association between discordant β-amyloid (Aβ) PET and CSF biomarkers a...
Background: Different tau biomarkers become abnormal at different stages of Alzheimer’s disease (AD)...
Objective: To investigate the association between discordant amyloid-β PET and CSF biomarkers at bas...
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's di...
Objective To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cort...
BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progre...
OBJECTIVE: To examine the cross-sectional associations between regional tau, β-amyloid (Aβ), and cor...
Background Combining PET amyloid-β and tau imaging may be critical for tracking disease progression ...
Background: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease prog...
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on function...
Aims: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especial...
BACKGROUND: Plasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimers di...
Abstract PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzhe...